Structure Therapeutics(NASDAQ) GPCR

Structure Therapeutics Inc. makes pills for chronic diseases. They replace painful injections with simple daily pills. These medicines help the body manage weight and heart health.

A Look at the Pipeline

• Aleniglipron: Oral pill targeting the glucagon-like-peptide-1 receptor, a recognized target for weight loss and type 2 diabetes mellitus.
• Amylin Program: Investigational oral therapies, including ACCG-2671 and ACCG-3535, designed to suppress food intake and reduce body weight.
• Incretin Programs: Preclinical small molecules targeting specific receptors to treat obesity and liver-mediated diseases like metabolic dysfunction-associated steatotic liver disease.
• Lung Therapy: Experimental medicine that acts as an antagonist for the lysophosphatidic acid 1 receptor to treat idiopathic pulmonary fibrosis, or lung scarring.

Major Moves and Milestones

• Initiated the ACCOMPLISH Phase 3 clinical program in August 2026 to evaluate its lead drug in up to 4,700 patients.
• Selected ACCG-3535 as a second development candidate in November 2025 after successful preclinical studies.
• Raised $701.5 million in net proceeds through a follow-on stock offering in December 2025.
• Obtained a $100 million upfront license fee for patent rights to certain oral metabolic medicines in early 2026.
• Expanded a stock offering agreement in May 2026 to potentially raise an additional $150 million.

The Technology Advantage

Structure uses a platform combining drug discovery and computational chemistry. This technology creates pills targeting proteins on the surface of cells. These proteins regulate many processes and are common medicine targets. Approximately one in every three medicines targets these pathways.

Vital Financial Facts

• Net loss was $182.1 million for the six-month period ended June 30, 2026.
• Research and development expenses rose to $166.6 million in the six-month period ended June 30, 2026, up 71% year over year.
• Cash, cash equivalents, and short-term investments totaled $1.3 billion as of June 30, 2026.
• General and administrative expenses reached $41.4 million in the six-month period ended June 30, 2026, up 42% year over year.

The Evolution of Structure

Structure has transitioned from an early-stage research firm to a clinical developer of oral metabolic therapies. Its shift toward Phase 3 trials and large cash reserves reflect its focus on bringing pill-based treatments to the obesity market.